A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine

Journal for Immunotherapy of Cancer
Hyun Jin ParkYeong-Min Park

Abstract

Dendritic cells (DCs) are professional antigen presenting cells (APCs), which can activate antigen-specific CD8+ T cell immunity, resulting in tumor clearance. Immature DCs are usually stimulated by various adjuvants through their immune receptors. Among them, Toll-like receptor 4 (TLR4) has an important role in activating DCs to cause their maturation. In fact, TLR4 is well-known to induce innate and adaptive immune responses against various external microbial or internal damage associated molecular patterns (DAMP). LPS is widely regarded as a strong stimulator of TLR4 signaling. However, LPS is inappropriate for use in humans since it is an endotoxin. Unfortunately, other TLR4 ligands such as HMGB1 or heat shock proteins have weak adjuvant effects. Therefore, there is a need to identify novel, biocompatible, strong, TLR4 ligands. 40S ribosomal protein S3 (RPS3) was screened through pull-down assay using TLR4. BMDCs from wild type (WT) and TLR4 knock-out mice were treated by RPS3 to identify the activation and maturation of DCs. T cell generation including memory T cells, tumor prevention, and treatment experiments were performed with BMDCs based vaccination. Also, human DCs originated from patients were treated by RPS3 to con...Continue Reading

References

Aug 1, 1980·International Journal of Cancer. Journal International Du Cancer·S TsuchiyaK Tada
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Jun 3, 2004·Nature Reviews. Immunology·Seung-Yong Seong, Polly Matzinger
Jun 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Davorka MessmerNicholas Chiorazzi
Apr 26, 2007·Nature Reviews. Immunology·Luke A J O'Neill, Andrew G Bowie
Feb 29, 2008·Cytokine·Yong-Chen LuPamela S Ohashi
Dec 9, 2008·Biochimica Et Biophysica Acta·Tae-Sung KimJoon Kim
Jun 13, 2009·Nature Reviews. Immunology·Teunis B H Geijtenbeek, Sonja I Gringhuis
Jun 18, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ivan Zanoni, Francesca Granucci
May 31, 2011·Maturitas·Eddie TharaDavid I Quinn
Oct 14, 2011·Viruses·Mikayla R ThompsonKatherine A Fitzgerald
Dec 20, 2011·BJU International·Giuseppe Di LorenzoCarlo Buonerba
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
May 18, 2013·Nature Reviews. Immunology·Luke A J O'NeillAndrew G Bowie
Jul 31, 2013·Immunity·Karolina Palucka, Jacques Banchereau
Jan 13, 2015·Annual Review of Immunology·Sky W BrubakerJonathan C Kagan
Jul 28, 2015·The Journal of Clinical Investigation·Cornelis J M MeliefSjoerd H van der Burg

❮ Previous
Next ❯

Citations

Nov 13, 2020·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Dmitri Graifer, Galina Karpova
Dec 11, 2020·Experimental & Molecular Medicine·Gun-Young JangYeong-Min Park
Jun 15, 2021·Journal of Immunology Research·Saghar PahlavanneshanMohsen Basiri

❮ Previous
Next ❯

Methods Mentioned

BETA
pull-down
PMA
Flow Cytometry
Assay
ELISA
electrophoresis
immunoprecipitation

Software Mentioned

SPSS Statistics Base

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.